Nicole LaBrosse compensation by year
HALOZYME THERAPEUTICS Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $546,188 | $568,188 | $604,188 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $1,800,055 | $2,635,082 | $2,975,129 |
| Option awards | $1,200,001 | $465,006 | $525,004 |
| Non-equity incentive | $291,391 | $537,960 | $462,203 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $11,784 | $12,040 | $12,290 |
| Total | $3,849,419 | $4,218,276 | $4,578,814 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: HALOZYME THERAPEUTICS, INC. DEF 14A filed March 23, 2026, accession 0001159036-26-000041, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 28,662 | $1,928,953 | — |
| RSU | 26,660 | $1,794,218 | — |
| RSU | 21,327 | $1,435,307 | — |
| RSU | 20,063 | $1,350,240 | — |
| PSU | 14,383 | $967,976 | — |
| PSU | 13,351 | $898,522 | — |
| RSU | 10,658 | $717,283 | — |
| RSU | 7,448 | $501,250 | — |
| RSU | 5,682 | $382,399 | — |
| RSU | 5,093 | $342,759 | — |
| PSU | 2,842 | $191,267 | — |
| Option | 15,017 | — | $40.56 |
Per the Outstanding Equity Awards at Fiscal Year-End table in HALOZYME THERAPEUTICS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 15 award rows shown.
Change-in-control & termination
estimated payments HALOZYME THERAPEUTICS discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Death | — | $6,083,247 | — | $6,083,247 |
| Change in control and involuntary termination | $1,359,423 | $12,321,259 | $81,352 | $13,762,034 |
| Change in control and resignation for good reason | $1,359,423 | $12,321,259 | $81,352 | $13,762,034 |
| Involuntary termination without cause | $906,282 | $5,780,935 | $36,879 | $6,724,096 |
| Disability | — | $6,083,247 | — | $6,083,247 |
Per the Potential Payments Upon Termination or Change in Control table in HALOZYME THERAPEUTICS, INC.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
HALOZYME THERAPEUTICS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Helen Torley | President and Chief Executive Officer | $23,166,223 |
| Nicole LaBrosse · this page | Senior Vice President, Chief Financial Officer | $4,578,814 |
| Mark Snyder | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $4,531,568 |
| Cortney Caudill | Senior Vice President, Chief Operating Officer | $3,202,906 |
| Michael LaBarre | Former Senior Vice President, Chief Technical Officer | $2,053,642 |
The full HALOZYME THERAPEUTICS compensation record
free company briefThis page is one person within HALOZYME THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order HALOZYME THERAPEUTICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are HALOZYME THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat